Vita Life Sciences (ASX:VLS) Beneish M-Score: -2.65 (As of Jun. 26, 2026)

What is Vita Life Sciences Beneish M-Score?

Vita Life Sciences ASX:VLS 94 Beneish M-Score is -2.65 as of Jun. 26, 2026. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 911 Drug Manufacturers companies, Vita Life Sciences ranks better than 63.67% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.65 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vita Life Sciences's Beneish M-Score or its related term are showing as below:

ASX:VLS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.79 Med: -2.45 Max: -1.86
Current: -2.65

During the past 13 years, the highest Beneish M-Score of Vita Life Sciences was -1.86. The lowest was -2.79. And the median was -2.45.

Vita Life Sciences Beneish M-Score Related Terms

Vita Life Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Vita Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vita Life Sciences Beneish M-Score Chart

Vita Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

-2.06

-1.86

-2.48

-2.28

-2.65

Vita Life Sciences Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Beneish M-Score	Get a 7-Day Free Trial															-2.48	0.00	-2.28	0.00	-2.65

ASX:VLS vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vita Life Sciences Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vita Life Sciences's Beneish M-Score falls into.

Save Embed

94GF Score

Vita Life Sciences Ltd ASX:VLS

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vita Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vita Life Sciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.9691

0.528 * 0.9717

0.404 * 1.321

0.892 * 1.1731

0.115 * 0.7487

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.0251

4.679 * -0.069425

0.327 * 1.168

-2.65

This Year (Dec25) TTM:

Last Year (Dec24) TTM:

Total Receivables was A$13.64 Mil.
Revenue was A$93.27 Mil.
Gross Profit was A$57.04 Mil.
Total Current Assets was A$65.85 Mil.
Total Assets was A$82.36 Mil.
Property, Plant and Equipment(Net PPE) was A$12.48 Mil.
Depreciation, Depletion and Amortization(DDA) was A$1.01 Mil.
Selling, General, & Admin. Expense(SGA) was A$39.87 Mil.
Total Current Liabilities was A$24.17 Mil.
Long-Term Debt & Capital Lease Obligation was A$1.91 Mil.
Net Income was A$10.44 Mil.
Gross Profit was A$-0.27 Mil.
Cash Flow from Operations was A$16.43 Mil.

Total Receivables was A$12.00 Mil.
Revenue was A$79.51 Mil.
Gross Profit was A$47.24 Mil.
Total Current Assets was A$58.90 Mil.
Total Assets was A$71.89 Mil.
Property, Plant and Equipment(Net PPE) was A$10.33 Mil.
Depreciation, Depletion and Amortization(DDA) was A$0.61 Mil.
Selling, General, & Admin. Expense(SGA) was A$33.15 Mil.
Total Current Liabilities was A$19.27 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.21 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(13.642 / 93.27)	/	(11.999 / 79.505)
	=	0.146264	/	0.150921
	=	0.9691

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(47.241 / 79.505)	/	(57.036 / 93.27)
	=	0.594189	/	0.611515
	=	0.9717

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (65.845 + 12.484) / 82.362)	/	(1 - (58.898 + 10.329) / 71.892)
	=	0.048967	/	0.037069
	=	1.321

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	93.27	/	79.505
	=	1.1731

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.612 / (0.612 + 10.329))	/	(1.008 / (1.008 + 12.484))
	=	0.055936	/	0.074711
	=	0.7487

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(39.865 / 93.27)	/	(33.148 / 79.505)
	=	0.427415	/	0.41693
	=	1.0251

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((1.911 + 24.165) / 82.362)	/	((0.214 + 19.274) / 71.892)
	=	0.316602	/	0.271073
	=	1.168

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(10.435 - -0.273	-	16.426)	/	82.362
	=	-0.069425

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vita Life Sciences has a M-score of -2.65 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.65 mean?

Vita Life Sciences (ASX:VLS) has a Beneish M-Score of -2.65 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vita Life Sciences and its competitors. According to the industry distribution chart, Vita Life Sciences ranks #331 out of 911 companies in the Drug Manufacturers industry, placing it in the top 36.3%.

Is Vita Life Sciences' Beneish M-Score too high?

Vita Life Sciences' current Beneish M-Score is -2.65. Based on the distribution chart, Vita Life Sciences ranks #331 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Vita Life Sciences' Beneish M-Score compare to ZTS?

According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #331 out of 911 companies for Beneish M-Score. This puts Vita Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Drug Manufacturers company?

A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vita Life Sciences and its competitors. Vita Life Sciences's current Beneish M-Score is -2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vita Life Sciences stock overvalued right now?

Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current Beneish M-Score is -2.65. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Beneish M-Score is -2.65 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?

Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued. The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47. GuruFocus considers Vita Life Sciences to be Fairly Valued.

Key valuation signals for ASX:VLS:

Beneish M-Score: -2.65
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vita Life Sciences Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ASX:SNT ASX:MVP ASX:LGP ASX:VIT ASX:PKP ASX:IDT ASX:EPN ASX:ECS ASX:PER ASX:CAN XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address 1-5 Chalmers Crescent, Suite 802, Level 8, Mascot, Sydney, NSW, AUS, 2020

Website https://www.vitalifesciences.com

Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.

94GF Score

Get the complete analysis for ASX:VLS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.50

Price

A$2.47

GF Value

View ASX:VLS Analysis

See Beneish M-Score data for all stocks →